Tonix Pharmaceuticals, a pharmaceutical company, completed the acquisition of Upsher-Smith Laboratories, a trusted pharmaceutical company. Financial terms were not disclosed. “This agreement is part of Upsher-Smith’s strategy to focus with even greater precision on our mission of delivering high-value, high-quality generics and novel therapies to customers. While we remain committed to our branded CNS products, this divestment allows us to optimize the value of these two migraine medications.” Rich Fisher, Upsher-Smith President and COO.